The Trump administration agreed to drop a controversial pilot that would have allowed drugmakers to give post-sales rebates ...
Centene outperformed in the fourth quarter, while predicting earnings growth in 2026 — a rarity among managed care companies’ generally dour outlooks.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results